ABCL AbCellera Biologics Inc.
AbCellera Biologics Inc. (ABCL) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
Where they traded
Last open-market purchase: November 13, 2026 , by Booth Andrew .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Booth Andrew | Chief Financial Officer | Buy | 8,600 | $11.33 | $97.4K | 491,400 | |
| Thermopylae Holdings Ltd. | 10% Owner | Buy | 60,565 | $11.54 | $698.9K | 56,194,662 | |
| Hayden Michael R | Director | Buy | 53,613 | $10.64 | $570.4K | 1,373,397 |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.